Diamonds and Dogs
12/11/17
Bluebirds are smiling today. Biotech, Bluebird Bio (BLUE) is up 16% to new highs thanks to positive drug trials for patients with advanced forms of the deadly blood cancer known as multiple myeloma. Bluebird Bio combined with Celgene presented that a 94% or 17 of 18 patients in their study exhibited objective response to the experimental cell-base therapy. Goldman Sachs upgraded Bluebird Bio with a $310 price target. Celgene is up 2%.
Fed Ex (FDX) can't win during the holiday season. The shipping giant is down a percent during their busiest season of the year. Between Thanksgiving and Christmas, UPS, FedEx, and United States Postal Service will deliver 2 billion packages, 70% from the levels in 2010. Fed Ex and UPS typically see their margins decrease this time of year, not increase due to hiring more season workers and paying overtime to the full time drivers. And guess who gets blamed when a package isn't delivered.
Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.